Last edition
News about "IMAgINATION Phase 3 Study"
Roche's Sefaxersen Cuts Proteinuria in Phase 3 IgAN Trial
Roche has announced new phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN).
IMAgINATION Phase 3 Study | 27/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members